tiprankstipranks
Capricor Therapeutics, Inc. (CAPR)
NASDAQ:CAPR
US Market
CAPR
Capricor Therapeutics
RESEARCH TOOLSreports
Want to see CAPR full AI Analyst Report?

Capricor Therapeutics (CAPR) Stock Forecast & Price Target

1,339 Followers
See the Price Targets and Ratings of:

CAPR Analyst Ratings

Hold
10Ratings
Hold
0 Buy
10 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Capricor
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

CAPR Stock 12 Month Forecast

Average Price Target

$4.90
▼(-75.13% Downside)
Based on 10 Wall Street analysts offering 12 month price targets for Capricor Therapeutics in the last 3 months. The average price target is $4.90 with a high forecast of $7.00 and a low forecast of $2.00. The average price target represents a -75.13% change from the last price of $19.70.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","16":"$16","31":"$31","8.5":"$8.5","23.5":"$23.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.90</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,8.5,16,23.5,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.85,4.092307692307692,4.334615384615384,4.576923076923077,4.819230769230769,5.061538461538461,5.303846153846154,5.546153846153846,5.788461538461538,6.030769230769231,6.273076923076923,6.515384615384615,6.757692307692308,{"y":7,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.85,3.930769230769231,4.0115384615384615,4.092307692307693,4.173076923076923,4.253846153846154,4.334615384615385,4.415384615384616,4.496153846153846,4.5769230769230775,4.657692307692308,4.7384615384615385,4.81923076923077,{"y":4.9,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.85,3.707692307692308,3.5653846153846156,3.4230769230769234,3.2807692307692307,3.138461538461539,2.996153846153846,2.853846153846154,2.7115384615384617,2.5692307692307694,2.426923076923077,2.2846153846153845,2.1423076923076927,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.9,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.33,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.82,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.51,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.65,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.86,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.09,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.86,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.12,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.91,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.53,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.07,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.85,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$7.00Average Price Target$4.90Lowest Price Target$2.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
B. Riley Securities Analyst forecast on CAPR
Madison Elsaadi
B. Riley Securities
B. Riley Securities
$10→$5
Hold
-74.62%
Downside
Downgraded
07/31/26
B. Riley Securities Reaffirms Their Buy Rating on Capricor Therapeutics (CAPR)
Maxim Group Analyst forecast on CAPR
Jason McCarthy
Maxim Group
Maxim Group
―
Hold
―
Downgraded
07/31/26
Capricor Therapeutics downgraded to Hold from Buy at MaximCapricor Therapeutics downgraded to Hold from Buy at Maxim
H.C. Wainwright Analyst forecast on CAPR
Joseph Pantginis
H.C. Wainwright
H.C. Wainwright
―
Hold
―
Downgraded
07/30/26
Analysts Are Neutral on Top Healthcare Stocks: Boston Scientific (BSX), Capricor Therapeutics (CAPR)
JonesTrading Analyst forecast on CAPR
Catherine Novack
JonesTrading
JonesTrading
―
Hold
―
Downgraded
07/30/26
Capricor Therapeutics downgraded to Hold from Buy at JonesResearchCapricor Therapeutics downgraded to Hold from Buy at JonesResearch
Oppenheimer Analyst forecast on CAPR
Leland Gershell
Oppenheimer
Oppenheimer
―
Hold
―
Downgraded
07/30/26
Capricor Therapeutics downgraded to Perform from Outperform at OppenheimerCapricor Therapeutics downgraded to Perform from Outperform at Oppenheimer
Piper Sandler Analyst forecast on CAPR
Edward Tenthoff
Piper Sandler
Piper Sandler
$58→$2
Hold
-89.85%
Downside
Downgraded
07/30/26
Capricor Therapeutics downgraded to Neutral from Overweight at Piper SandlerCapricor Therapeutics downgraded to Neutral from Overweight at Piper Sandler
Alliance Global Partners Analyst forecast on CAPR
Matthew Venezia
Alliance Global Partners
Alliance Global Partners
$51→$7
Hold
-64.47%
Downside
Reiterated
07/30/26
Capricor Therapeutics downgraded to Neutral from Buy at Alliance GlobalCapricor Therapeutics downgraded to Neutral from Buy at Alliance Global
Ladenburg Thalmann & Co. Analyst forecast on CAPR
Rick Bienkowski
Ladenburg Thalmann & Co.
Ladenburg Thalmann & Co.
―
Hold
―
Downgraded
07/30/26
Capricor Therapeutics downgraded to Neutral from Buy at LadenburgCapricor Therapeutics downgraded to Neutral from Buy at Ladenburg
Cantor Fitzgerald Analyst forecast on CAPR
Kristen Kluska
Cantor Fitzgerald
Cantor Fitzgerald
$62→$3.5
Hold
-82.23%
Downside
Downgraded
07/29/26
Capricor downgraded to Neutral from Overweight at Cantor FitzgeraldCapricor downgraded to Neutral from Overweight at Cantor Fitzgerald
Roth MKM Analyst forecast on CAPR
Boobalan Pachaiyappan
Roth MKM
Roth MKM
$38→$7
Hold
-64.47%
Downside
Downgraded
07/28/26
Analysts Offer Insights on Healthcare Companies: Capricor Therapeutics (NASDAQ: CAPR) and Thermo Fisher (NYSE: TMO)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
B. Riley Securities Analyst forecast on CAPR
Madison Elsaadi
B. Riley Securities
B. Riley Securities
$10→$5
Hold
-74.62%
Downside
Downgraded
07/31/26
B. Riley Securities Reaffirms Their Buy Rating on Capricor Therapeutics (CAPR)
Maxim Group Analyst forecast on CAPR
Jason McCarthy
Maxim Group
Maxim Group
―
Hold
―
Downgraded
07/31/26
Capricor Therapeutics downgraded to Hold from Buy at MaximCapricor Therapeutics downgraded to Hold from Buy at Maxim
H.C. Wainwright Analyst forecast on CAPR
Joseph Pantginis
H.C. Wainwright
H.C. Wainwright
―
Hold
―
Downgraded
07/30/26
Analysts Are Neutral on Top Healthcare Stocks: Boston Scientific (BSX), Capricor Therapeutics (CAPR)
JonesTrading Analyst forecast on CAPR
Catherine Novack
JonesTrading
JonesTrading
―
Hold
―
Downgraded
07/30/26
Capricor Therapeutics downgraded to Hold from Buy at JonesResearchCapricor Therapeutics downgraded to Hold from Buy at JonesResearch
Oppenheimer Analyst forecast on CAPR
Leland Gershell
Oppenheimer
Oppenheimer
―
Hold
―
Downgraded
07/30/26
Capricor Therapeutics downgraded to Perform from Outperform at OppenheimerCapricor Therapeutics downgraded to Perform from Outperform at Oppenheimer
Piper Sandler Analyst forecast on CAPR
Edward Tenthoff
Piper Sandler
Piper Sandler
$58→$2
Hold
-89.85%
Downside
Downgraded
07/30/26
Capricor Therapeutics downgraded to Neutral from Overweight at Piper SandlerCapricor Therapeutics downgraded to Neutral from Overweight at Piper Sandler
Alliance Global Partners Analyst forecast on CAPR
Matthew Venezia
Alliance Global Partners
Alliance Global Partners
$51→$7
Hold
-64.47%
Downside
Reiterated
07/30/26
Capricor Therapeutics downgraded to Neutral from Buy at Alliance GlobalCapricor Therapeutics downgraded to Neutral from Buy at Alliance Global
Ladenburg Thalmann & Co. Analyst forecast on CAPR
Rick Bienkowski
Ladenburg Thalmann & Co.
Ladenburg Thalmann & Co.
―
Hold
―
Downgraded
07/30/26
Capricor Therapeutics downgraded to Neutral from Buy at LadenburgCapricor Therapeutics downgraded to Neutral from Buy at Ladenburg
Cantor Fitzgerald Analyst forecast on CAPR
Kristen Kluska
Cantor Fitzgerald
Cantor Fitzgerald
$62→$3.5
Hold
-82.23%
Downside
Downgraded
07/29/26
Capricor downgraded to Neutral from Overweight at Cantor FitzgeraldCapricor downgraded to Neutral from Overweight at Cantor Fitzgerald
Roth MKM Analyst forecast on CAPR
Boobalan Pachaiyappan
Roth MKM
Roth MKM
$38→$7
Hold
-64.47%
Downside
Downgraded
07/28/26
Analysts Offer Insights on Healthcare Companies: Capricor Therapeutics (NASDAQ: CAPR) and Thermo Fisher (NYSE: TMO)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
ZURAZura Bio
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

CAPR Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
7
17
12
15
5
Buy
5
8
4
4
1
Hold
0
0
0
10
10
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
12
25
16
29
16
In the current month, CAPR has received 6 Buy Ratings, 10 Hold Ratings, and 0 Sell Ratings. CAPR average Analyst price target in the past 3 months is 4.90.
Each month's total comprises the sum of three months' worth of ratings.

CAPR Financial Forecast

CAPR Earnings Forecast

Next quarter’s earnings estimate for CAPR is -$0.59 with a range of -$0.64 to -$0.43. The previous quarter’s EPS was -$0.59. CAPR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 58.33% of the time in the same period. In the last calendar year CAPR has Performed in-line its overall industry.
Next quarter’s earnings estimate for CAPR is -$0.59 with a range of -$0.64 to -$0.43. The previous quarter’s EPS was -$0.59. CAPR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 58.33% of the time in the same period. In the last calendar year CAPR has Performed in-line its overall industry.

CAPR Sales Forecast

Next quarter’s sales forecast for CAPR is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. CAPR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 66.67% of the time in the same period. In the last calendar year CAPR has Performed in-line its overall industry.
Next quarter’s sales forecast for CAPR is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. CAPR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 66.67% of the time in the same period. In the last calendar year CAPR has Performed in-line its overall industry.

CAPR Stock Forecast FAQ

What is CAPR’s average 12-month price target, according to analysts?
Based on analyst ratings, Capricor Therapeutics, Inc.’s 12-month average price target is 4.90.
    What is CAPR’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CAPR, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is CAPR a Buy, Sell or Hold?
        Capricor Therapeutics, Inc. has a consensus rating of Hold which is based on 0 buy ratings, 10 hold ratings and 0 sell ratings.
          What is Capricor Therapeutics, Inc.’s price target?
          The average price target for Capricor Therapeutics, Inc. is 4.90. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst price target is $7.00 ,the lowest forecast is $2.00. The average price target represents -75.13% Decrease from the current price of $19.7.
            What do analysts say about Capricor Therapeutics, Inc.?
            Capricor Therapeutics, Inc.’s analyst rating consensus is a Hold. This is based on the ratings of 10 Wall Streets Analysts.
              How can I buy shares of CAPR?
              Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.